Rick Heida

Mr. Rick Heida

Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Expert Review of Vaccines
Verified
Journal Article
Open access
Rick HeidaRick Heida
Rick Heida
Wouter L.J. HinrichsWouter L.J. Hinrichs
Wouter L.J. Hinrichs
HFHenderik Frijlink
Henderik Frijlink
As underlined by the late 2019 outbreak of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), vaccination remains the cornerstone of global health-care. Although vaccines for SARS-CoV-2 ...

1 January 2021 in Drug Discovery Today
Verified
Journal Article
Open access
Rick HeidaRick Heida
Rick Heida
YBYoshita C. Bhide
Yoshita C. Bhide
MGMatteo Gasbarri
Matteo Gasbarri
ÖKÖzgün Kocabiyik
Özgün Kocabiyik
FSFrancesco Stellacci
Francesco Stellacci
HFHenderik W. Frijlink
Henderik W. Frijlink
• Entry inhibitors might overcome the limitation of viral mutation. • Antiviral research benefits from a broad-spectrum approach. • Sialic acids can serve as a platform to create broad-spectrum antiviral drugs. • Sialic-acid-targeting drugs such as DAS-181 are promising antiviral strategies. • Multivalency is crucial when designing sialic-acid-based receptor analogues.

12 June 2018 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GGGiorgio Gabarrini
Giorgio Gabarrini
Rick HeidaRick Heida
Rick Heida
NINienke van Ieperen
Nienke van Ieperen
MCMichael Curtis
Michael Curtis
AWArie Jan van Winkelhoff
Arie Jan van Winkelhoff
JDJan Maarten Van Dijl
Jan Maarten Van Dijl
The periodontal pathogen Porphyromonas gingivalis has been invoked in the autoimmune disease rheumatoid arthritis (RA). This association relates to the peptidylarginine deiminase of P. gingivalis (PPAD), an enzyme capable of citrullinating human proteins and potentially contributing to loss of tolerance to citrullinated proteins in RA. PPAD is both retained in the outer membrane (OM) of P. gingivalis cells and secreted into the extracellular milieu, where it is detected in a soluble form and in association with outer membrane vesicles (OMVs). Recent studies showed that certain P. gingivalis proteins are retained in the OM through modification with an A-type lipopolysaccharide (A-LPS). Here, we investigated the possible involvement of A-LPS modification in the association of PPAD to the OM and OMVs. The results indicate that the OM- and OMV-associated PPAD is A-LPS-modified. The modified PPAD species is of low abundance in particular clinical isolates of P. gingivalis, which is not due to defects in the overall synthesis of A-LPS-modified proteins but, rather, to particular traits of the respective PPAD proteins. Lastly, we show that OMV association protects the A-LPS-modified PPAD from proteolytic degradation. Altogether, our observations show that A-LPS modification contributes to OM(V) sorting and ‘protective secretion’ of PPAD.

31 October 2023 in mBio
Verified
Journal Article
Open access
Rick HeidaRick Heida
Rick Heida
HFHenderik W. Frijlink
Henderik W. Frijlink
Wouter L.J. HinrichsWouter L.J. Hinrichs
Wouter L.J. Hinrichs
Many of the current pandemic threats are caused by viruses that infect the respiratory tract. Remarkably though, the majority of vaccines and antiviral drugs are administered via alternative routes. In this perspective, we argue that the pulmonary route of administration deserves more attention in the search for novel therapeutic strategies against respiratory virus infections. Firstly, vaccines administered at the viral portal of entry can induce a broader immune response, employing the mucosal arm of the immune system; secondly, direct administration of antiviral drugs at the target site leads to superior bioavailability, enabling lower dosing and reducing the chance of side effects. We further elaborate on why the pulmonary route may induce a superior effect compared to the intranasal route of administration and provide reasons why dry powder formulations for inhalation have significant advantages over standard liquid formulations.

5 April 2023 in Journal of Controlled Release
Verified
Journal Article
Open access
Rick HeidaRick Heida
Rick Heida
RARenate Akkerman
Renate Akkerman
PSPaulo H. Jacob Silva
Paulo H. Jacob Silva
ALAnke J. Lakerveld
Anke J. Lakerveld
DODaniel Ortiz
Daniel Ortiz
Wouter L.J. HinrichsWouter L.J. Hinrichs
Wouter L.J. Hinrichs

28 June 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Rick HeidaRick Heida
Rick Heida
PHPaul Hagedoorn
Paul Hagedoorn
MMMelle C. van Meel
Melle C. van Meel
JPJurrie E. R. Prins
Jurrie E. R. Prins
FSFrederike Simonis
Frederike Simonis
Wouter L.J. HinrichsWouter L.J. Hinrichs
Wouter L.J. Hinrichs
A challenge in the development of dry powder formulations for inhalation is the poor reproducibility of their administration to small laboratory animals. The currently used devices for the pulmonary administration of dry powder formulations to small rodents often function sub-optimally as they use the same puff of air for both powder dispersion and aerosol delivery. As a result, either the air volume and flow rate are too low for complete powder deagglomeration or they are too high for effective aerosol delivery to the lungs of the animal. Therefore, novel and better devices are desired. We here present an aerosol generator designed to administer a pre-generated aerosol to the lungs of mice. By mapping the complex relationship between the airflow rate, delivery time and emitted dose, we were able to control the amount of powder being delivered from the aerosol generator. The emitted aerosol had a size range favorable for lung deposition and could be measured reproducibly. Nevertheless, in vivo fluorescent imaging still revealed considerable differences between the mice in terms of the dose deposited and the distribution of powder over the lungs, suggesting that a certain biological variation in lung deposition is inevitable.